VTP-195183 Drug Asset Due Diligence Report 2026

This VTP-195183 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether VTP-195183 can convert its Small molecule drug profile and RARα biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	VTP-195183 (query alias: VTP-195183)
Modality / target	Small molecule drug; RARα; RARα agonists
Highest global status	Phase 2
Originator	Allergan UC
Active developers	Io Therapeutics, Inc.

The MCP disease footprint includes Acute Myeloid Leukemia, Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02749708	Phase 1	Terminated	13	Primary endpoint not disclosed in English source
NCT00675870	Phase 2	Unknown status	65	Primary endpoint not disclosed in English source
NCT00670150	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML

Phase 1; n=11; evaluation: Positive. Reported fields: AE = cAE included hypertriglyceridemia, fatigue, dyspnea, and edema. 3 pts at the first dose level developed asymptomatic Grade 3 hypertriglyceridemia

A phase I and pharmacokinetic clinical trial of the orally administered retinoic acid receptor-α Agonist, AGN 195183

Phase 1; n=15; evaluation: Positive. Reported fields: Adverse Event: gr 3 elevation of alkaline phosphatase = 2 of 4 pts treated had gr 3 elevation of alkaline phosphatase

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

VTP-195183 addresses Acute Myeloid Leukemia, Multiple Myeloma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 18 matched transaction record(s) under the scope “target-level comparable: RARα.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: RARα records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-10	WinHealth Pharma and Jacobson Pharma Group Partner to Develop and Commercialize ARSENOL® in the Chinese Mainland	Approved	Financial terms not disclosed
2026-04-01	Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India	Approved	Financial terms not disclosed
2025-04-17	Sol-Gel and Galderma entered an mutual termination for the the exclusive five-year license agreement for EPSOLAY and TWYNEO	Approved	US$24.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy”. The milestone feed surfaced a patent-application signal described as “Synthesis of tetrahydronaphthalenols and uses thereof”. The milestone feed surfaced a patent-application signal described as “RAR selective agonists in combination with immune modulators for cancer immunotherapy”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO